In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Influence of diabetes mellitus on ischaemia burden and collateralization in chronic total coronary artery occlusion

Session Poster session 2

Speaker Ahmed Mohamed Salah Eldin Khedr Abdelaty

Event : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Coronary Imaging
  • Session type : Poster Session

Authors : AMKD Khedr (Leicester,GB), CA Budgeon (Leicester,GB), A Ladwiniec (Leicester,GB), S Hetherington (Kettering,GB), G Gulsin (Leicester,GB), A Singh (Leicester,GB), AH Gershlick (Leicester,GB), GP Mccann (Leicester,GB), JR Arnold (Leicester,GB)

Authors:
AMKD Khedr1 , CA Budgeon1 , A Ladwiniec2 , S Hetherington3 , G Gulsin1 , A Singh1 , AH Gershlick1 , GP Mccann1 , JR Arnold1 , 1University of Leicester, Cardiovascular sciences - Leicester - United Kingdom of Great Britain & Northern Ireland , 2University Hospitals of Leicester NHS Trust, Cardiovascular department - Leicester - United Kingdom of Great Britain & Northern Ireland , 3Kettering General Hospital, Cardiovascular department - Kettering - United Kingdom of Great Britain & Northern Ireland ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii365

Background: Coronary chronic total occlusions (CTO) are present in up to one third of patients with coronary artery disease referred for invasive coronary angiography. In CTO-subtended myocardial territories, the development of collateral connections may mitigate against ischaemia and prevent necrosis. Type 2 diabetes mellitus (T2DM) is increasingly prevalent, and represents a potential risk factor for impaired collateral vessel growth. Using multiparametric cardiac magnetic resonance imaging (CMR),
Purpose: To ascertain the influence of T2DM on ischaemia burden, collateralization and infarction in patients with CTO.
Methods: We retrospectively studied 397 consecutive patients with CTO identified on invasive coronary angiography who were referred for clinical stress CMR at our institution between 2011-2018. CMR assessment comprised visual evaluation of myocardial first-pass perfusion, infarction and left ventricular systolic function. Using invasive coronary angiography, the degree of collateralisation distal to the CTO from contralateral vessels was graded according to the Rentrop classification.
Results: Of the 397 patients in the cohort (mean age 65±11 years, 84% male), 128 (32%) had T2DM. No significant between-group difference was observed in ejection fraction (50.6±12.4% in those with T2DM and 51.3±13.5%in those without T2DM, p=0.61). Similarly no differences were observed in wall motion score index (1.6±0.6 versus 1.5±0.5, respectively, p=0.16)or in the prevalence of infarction (71% versus 70%, p=0.76). In those with infarction, there was no difference in infarct size (as a percentage of left ventricular mass, 11.0±9.7%in subjects with T2DM and 10.5±8.3% in those without, p=0.65). However, in those subjects with T2DM, significant (= 10%) ischaemia burden was more prevalent (53% vs 40%, p=0.03, and well-formed collaterals (Rentrop grade 3) were less prevalent (34% versus 45%, respectively, p=0.03). 
Conclusion: In this observational study involving patients with CTOs, the presence of T2DM was associated with less well developed coronary collaterals and higher ischaemia burden. Whether the presence of coexisting T2DM in patients with CTOs may impact long-term clinical outcome and revascularization decisions requires further study

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are